---

An official NHS document proves that NHS staff were told respiratory depressing drugs “should not be withheld due to inappropriate concerns” about using them to treat Covid-19; a respiratory disease.

Midazolam can cause serious or life-threatening breathing problems such as shallow, slowed, or temporarily stopped breathing that may lead to permanent brain injury or death, and UK regulators state that you should only receive midazolam in a hospital or doctor’s office that has the equipment that is needed to monitor your heart and lungs and to provide life-saving medical treatment quickly if your breathing slows or stops.

The drug, which is criminally used in palliative care in the United Kingdom despite not being on the WHO’s list of essential palliative care medicines, should also be used with extreme caution in elderly patients.

But despite this, Matt Hancock and the Department of Health ordered two years worth of Midazolam in March 2020 in response to the introduction of the first lockdown. A two year supply that was depleted by October of the same year.

The reason being that the elderly and vulnerable were denied treatment by the NHS; a policy that was part of a pandemic response four years in the planning, and instead put on end of life care which involved withdrawing their medication, depriving them of food and water, and pumping them full of midazolam and morphine until they died of starvation and dehydration.

Evidence suggests that the drug midazolam was used to prematurely end the lives of thousands upon thousands of people in the United Kingdom who you were told had died of Covid-19, and this can be clearly seen from the data on out of hospital prescribing for midazolam coinciding with the waves of all cause deaths and Covid-19 deaths in the UK, as well as the Amnesty and CQC reports which found the blanket use of Do Not Resuscitate orders being used in care homes without informing the residents or their families.

Serious illness in Covid-19 presents pneumonia and accompanying respiratory insufficiency. Therefore typical symptoms include breathlessness, cough, weakness and fever. We’re also told that people who suffer deteriorating respiratory failure and who do not receive intensive care, develop acute respiratory distress syndrome with severe breathlessness.

Despite this, NHS staff were told in ‘clinical guidance for symptom control for patients with Covid-19‘ that excessive doses of morphine and midazolam should be given to ease the symptoms of Covid-19.

The drug label information for Midazolam on the US National Library of Medicine clearly states that “Midazolam hydrochloride must never be used without individualization of dosage. The initial intravenous dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a normal healthy adult. Lower doses are necessary for older (over 60 years) or debilitated patients”

But despite this, NHS staff were told to up the dosage of Midazolam in all Covid-19 patients if they were suffering “persistent anxiety or agitation”. At no point were they instructed to individualise doses based on the age or fraility of the patient.

The warning label states that because of the “danger of hypoventilation, airway obstruction, or apnoea is greater in elderly patients and those with chronic disease states or decreased pulmonary reserve, and because the peak effect may take longer in these patients, increments should be smaller and the rate of injection slower.”

Perhaps NHS staff also knew this, but they were told within the clinical guidance provided to them that their concerns were “inappropriate”.

Confidential NHS documents clearly show that the elderly and vulnerable were to be denied treatment and put on the end of life pathway in response to a pandemic, and the evidence clearly shows this was put into practice.